R
Roger Stupp
Researcher at Northwestern University
Publications - 463
Citations - 73077
Roger Stupp is an academic researcher from Northwestern University. The author has contributed to research in topics: Temozolomide & Glioma. The author has an hindex of 93, co-authored 430 publications receiving 63025 citations. Previous affiliations of Roger Stupp include Merck & Co. & University of St. Gallen.
Papers
More filters
Journal ArticleDOI
RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).
Mark R. Gilbert,Meihua Wang,Kenneth Aldape,Roger Stupp,Monika E. Hegi,Kurt A. Jaeckle,Terri Armstrong,Jeffrey S. Wefel,Minhee Won,Deborah T. Blumenthal,Anita Mahajan,Christopher J. Schultz,Sara Erridge,Paul D. Brown,Arnab Chakravarti,Walter J. Curran,Minesh P. Mehta +16 more
TL;DR: This study confirmed the prognostic significance of MGMT methylation in GBM and demonstrated the feasibility of tumor tissue collection, molecular stratification and collection of patient outcomes in a large transatlantic intergroup trial and established this as a viable clinical trial paradigm.
Journal ArticleDOI
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial.
Martin J.B. Taphoorn,Linda Dirven,Andrew A. Kanner,Gitit Lavy-Shahaf,Uri Weinberg,S. Taillibert,Steven A. Toms,Jérôme Honnorat,Thomas C. Chen,Jan Sroubek,Carlos A. David,Ahmed Idbaih,Jacob C. Easaw,Chae-Yong Kim,Jordi Bruna,Andreas F. Hottinger,Yvonne Kew,Patrick Roth,Rajiv D. Desai,John L. Villano,Eilon D. Kirson,Zvi Ram,Roger Stupp +22 more
TL;DR: The addition of TTFields to standard treatment with temozolomide for patients with glioblastoma results in improved survival without a negative influence on HRQoL except for more itchy skin, an expected consequence from the transducer arrays.
Journal Article
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).
Michele Ghielmini,Shu Fang Hsu Schmitz,K. Burki,Gabriella Pichert,Daniel C. Betticher,Roger Stupp,M. Wernli,Andreas Lohri,Doris Schmitter,Francesco Bertoni,Thomas Cerny +10 more
TL;DR: In this paper, the anti CD-20 monoclonal antibody Rituximab has been reported in patients with follicular lymphoma and mantle-cell lymphoma (MCL).
Journal ArticleDOI
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Jaap C. Reijneveld,Martin J.B. Taphoorn,Corneel Coens,Jacoline E C Bromberg,Warren P. Mason,Khê Hoang-Xuan,Gail Ryan,Mohamed Ben Hassel,Roelien H. Enting,Alba A. Brandes,Antje Wick,Olivier Chinot,Michele Reni,Guy Kantor,Brian Thiessen,Martin Klein,Eugenie Verger,Christian Borchers,Peter Hau,Michael Back,Anja Smits,Vassilis Golfinopoulos,Thierry Gorlia,Andrew Bottomley,Roger Stupp,Brigitta G. Baumert,Brigitta G. Baumert,Brigitta G. Baumert +27 more
TL;DR: The results do not support the choice of temozolomide alone over radiotherapy alone in patients with high-risk low-grade glioma and the results for two key secondary endpoints: HRQOL and global cognitive functioning are reported.
Journal ArticleDOI
Standards of care and novel approaches in the management of glioblastoma multiforme
TL;DR: The standard treatment options for GBM are reviewed and the results obtained in clinical trials for promising novel approaches are evaluated, including the inhibition of angiogenesis, targeted approaches against molecular pathways, immunotherapies, and local treatment with low voltage electric fields.